Command Palette

Search for a command to run...

Clinical Trials · NCT00835848

Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

CompletedPhase 4Exenatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Rigshospitalet, Denmark
Enrollment
100
Start date
Jan 2009
Locations
1 site, Denmark
Primary endpoint
Infarct size by MRI
View Exenatide compound reference